Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 2, 2001 - Issue 4
Submit an article Journal homepage
181
Views
25
CrossRef citations to date
0
Altmetric
Review

Immunomodulatory drugs for multiple sclerosis: a systematic review of clinical and cost effectiveness

Andrew Clegg Southampton Health Technology Assessments Centre (SHTAC), Wessex Institute for Health Research and Development, University of Southampton, Biomedical Sciences Building, Bassett Crescent East, Southampton SO16 7PX, UK. [email protected]
&
Jackie Bryant Southampton Health Technology Assessments Centre (SHTAC), Wessex Institute for Health Research and Development, University of Southampton, Biomedical Sciences Building, Bassett Crescent East, Southampton SO16 7PX, UK. [email protected]
Pages 623-639 | Published online: 24 Feb 2005

Bibliography

  • THOMPSON AJ: Drug therapy in multiple sclerosis. Prescribersjournal (1999) 39(2):72–80.
  • POLMAN CH, UITDEHAAG BMJ: Drug treatment of multiple sclerosis. Br. Med. J. (2000) 321 :490–494.
  • COMPSTON A, EBERS GC, LASSMAN H et al.: Multiple Sclerosis. Churchill Livingstone, London (1998): Chapter 14.
  • •A useful source concerning MS.
  • DYER C: Ruling on interferon beta will hit all health authorities. Br. Med. J. (1997) 315:146.
  • BURNFIELD A, PRICE C, NAPIER JC et al.: Interferon beta in multiple sclerosis. Br. Med. J. (1997) 314:600.
  • CLEGG A, BRYANT J, MILNE R: Disease modifying drugs for multiple sclerosis: a rapid and systematic review. Health Technol. Assessment (2000) 4(9).
  • ••A rapid and systematic review of the clinical and costeffectiveness of eight disease-modifying drugs for MS.
  • JADAD AR, MOORE A, CARROLL D et al: Assessing the quality of reports of randomised clinical trials: is blinding necessary? Control. Clin. Trials (1996) 17:1–12.
  • •Description of a commonly used method for assessing the quality of RCTs.
  • RICHARDSON WS, DETSKY AS: Users' Guides to the Medical Literature VII. How to use a clinical decision analysis A. Are the results of the study valid. JAMA (1995) 273(16):1292–1295.
  • •Description of a method for assessing the quality of studies using decision analysis.
  • YUDKIN PL, ELLISON GW, GHEZZI A et al.: Overview of azathioprine treatment in multiple sclerosis. Lancet (1991) 338:1051–1055.
  • MILANESE C, LA MANTIA L, SALMAGGI A et al.: A double blind study on azathioprine efficacy in multiple sclerosis: final report. J Neurol (1993) 240:295–298.
  • STECK AJ, REGLI F, OCHSNER F et al.: Cyclosporine versus azathioprine in the treatment of multiple sclerosis: 12-month clinical and immunological evaluation. Eur. Neurol. (1990) 30:224–228.
  • EBERS GC, HOMMES O, HUGHES RAC et al: Randomiseddouble-blind placebo-controlled study of interferon-beta-1a in relapsing-remitting multiple sclerosis. Lancet (1998) 352:1498–1504.
  • JACOBS LD, COOKFAIR DL, RUDICK RA et al.: A Phase IIItrial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Multiple Sclerosis (1995) 1:118–135.
  • JACOBS LD, COOKFAIR DL, RUDICK RA et al.: Intramus-cular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann. Neurol. (1996) 39(3):285–294.
  • THE ONCE WEEKLY INTERFERON MS STUDY GROUP: Evidence of interferon 13-1 a dose response in relapsing-remitting MS. The OWIMS Study. Neurology (1999) 53:679–686.
  • OTTEN N: Comparison of drug treatments for multiple sclerosis. Canadian Co-ordinating Office for Health Technology Assessment (CCOHTA), Ottawa (1998).
  • NICHOLSON T, MILNE R: Beta Interferons (la and lb) in relapsing-remitting and secondary multiple sclerosis. Wessex Institute for Health Research and Development, Southampton (1999) Report No. 98.
  • IFNB MULTIPLE SCLEROSIS STUDY GROUP: Interferonbeta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicentre, random-ised, double-blind, placebo-controlled trial. Neurology (1993) 43:655–661.
  • IFNB MULTIPLE SCLEROSIS STUDY GROUP AND THE UNIVERSITY OF BRITISH COLUMBIA MS/MRI ANALYSIS GROUP: Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology (1995) 45 (7) :1277–1285.
  • KAPPOS L, POLMAN C, POZZILLI C et al.: Placebo- controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet (1998) 352 (9139):1491–1497.
  • •An example of a good quality RCT.
  • FORBES R, LEES A, WAUGH N et al.: Population based cost-utility study of interferon beta-1b in secondary progressive multiple sclerosis. Br. Med. J. (1999) 319:1529–1533.
  • KOBELT G, JONSSON L, HENRIKSSON F et al:Cost-utility of interferon beta-1b in secondary progressive multiple sclerosis. Intl. J. Technol Assess. HealthCare (2000) 1 6 (3)768–780.
  • PARKIN D, MCNAMEE P, JACOBY A et al.: A cost-utility analysis of interferon beta for multiple sclerosis. Health Technol. Assessment (1998) 2(4).
  • BROWN MG, MURRAY TJ, SKETRIS IS et al.: Cost-effectiveness of interferon beta-1b in slowing multiple sclerosis disability progression. Intl. J of TechnologyAssessment in Healthcare (2000) 1 6 (3) :751–767.
  • SIPE JC, ROMINE JS, KOZIOL JA et al.: Cladribine in treatment of chronic progressive multiple sclerosis. Lancet (1994) 344(8914):9–13.
  • BEUTLER E, SIPE JC, ROMINE JS et al.: The treatment ofchronic progressive multiple sclerosis with cladribine. Proc. Natl. Acad. Sci. USA (1 9 96) 93:1716-11720.
  • ROMINE JS, SIPE JC, KOZIOL JA et al.: A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis. Proc. Assoc. Am. Physicians (1999) 111:35–44.
  • RICE G, FILIPPI M: Cladribine and progressive MS - Clinical and MRI outcomes of a multicenter controlled trial. Neurology (2000) 54:1145–1155.
  • COMPSTON A, EBERS GC, LASSMAN H et al.: Multiple Sclerosis. Churchill Livingstone, London (1998):461.
  • KILLIAN JM, BRESSLER RB, ARMSTRONG RM et al.: Controlled pilot trial of monthly intravenous cyclophosphamide in multiple sclerosis. Arch. Neurol (1988) 45:27–30.
  • HAUSER SL, DAWSON DM, LEHRICH JR et al.: Intensiveimmunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange and ACTH. N Engl. J. Med. (1983) 308:173–180.
  • THE CANADIAN CO-OPERATIVE MULTIPLE SCLEROSIS STUDY GROUP: The Canadian cooperative trial of cyclophosphamide and plasma exchange in progres-sive multiple sclerosis. Lancet (1991) 337:441–446.
  • LIKOSKY WH, FIREMAN B, ELMORE R et al.: Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study. J. Neurol Neurosurg. Psychiatry (1991) 54:1055–1060.
  • WEINER HL, MACKIN GA, ORAV EJ et al.: Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group [see comments]. Neurology (1993) 43:910–918.
  • NICHOLSON T, MILNE R: Copolymer 1 in relapsing-remitting multiple sclerosis. Wessex Institute for Health Research and Development, Southampton (1996). Report No. 63.
  • WEINSTEIN A, SCHWID SIL, SCHIFFER RB et al: Neurop-sychologic status in multiple sclerosis after treatment with glatiramer. Arch. Neurol. (1999) 47:319–324.
  • LA MANTIA L, MILANESE C, D'AMICO R: Meta analysis ofclinical trials with Copolymer 1 in multiple sclerosis. Eur. Neurol (2000) 43:189–193.
  • JOHNSON KP, BROOKS BR, COHEN JA et al.: Copolymer1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a Phase III multicenter, double- blind, placebo-controlled trial. Neurology (1995) 45 (7) :1268–1276.
  • BORNSTEIN MB, MILLER A, SLAGLE S et al: A pilot trial ofCop 1 in exacerbating-remitting multiple sclerosis. N Engl. J. Med. (1987) 317:408–414.
  • ACHIRON A, GABBAY U, GILAD R et al.: Intravenousimmunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology (1998) 50:398–402.
  • •An example of a good quality RCT.
  • FAZEKAS F, DEISENHAMMER F, STRASSER FUCHS S et al.: Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immuno-globulin in Multiple Sclerosis Study Group. Lancet (1997) 349:589–593.
  • •An example of a good quality RCT.
  • SORENSEN PS, WANSCHER B, JENSEN CV et al.: Intrave-nous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology (1998) 50:1273–1281.
  • GOODKIN DE, RUDICK RA, VANDERBRUG MEDENDORPS et al: low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis [see comments]. Ann. Neurol (1995) 37:30–40.
  • CURRIER RD, HAERER AF, MEYDRECH EF: Iipw dose oralmethotrexate treatment of multiple sclerosis: a pilot study [published erratum appears in J Neurol Neurosurg Psychiatry 1994 Apr;57:528]. j Neurol. Neurosurg. Psychiatry (1993) 56:1217–1218.
  • MILLEFIORINI E, GASPERINI C, POZZILLI C et al.: Randomized placebo-controlled trial of mitoxantrone in relapsing- remitting multiple sclerosis: 24-month clinical and MRI outcome. J. Neurol. (1997) 244:153–159.
  • EDAN G, MILLER D, CLANET M et al: Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J. Neurol. Neurosurg. Psychiatry (1997) 62:112–118.
  • JUNI P, WITSCHI A, BLOCH R et al.: The hazards of scoring the quality of clinical trials for meta-analysis. JAMA (1999) 282:1054–1060.
  • EVANS AC, FRANK JA, ANTEL JP et al: The role of MRI in clinical trials of multiple sclerosis: comparison of imaging process technique. Ann. Neurol. (1997) 41:125–132.
  • KAPPOS L, MOERI D, RAUDE EW: Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impair-ment in multiple sclerosis; a meta-analysis. Lancet (1999) 353:964–969.
  • HENRIKSSON F, FREDRIKSON S, JONSSON B: Costs, quality of life and disease severity in multiple sclerosis: a population-based cross sectional study in Sweden .Stockholm School of Economics, Stockholm (2000). Working paper no. 361.

Websites

  • http://www.nice.org.uk/article.asp?a = 13526 NICE website press release (2000).
  • http://www.agatha.york.ac.uk
  • •NHS Centre for Reviews and Dissemination website providing access to systematic reviews of health technolo-gies, economic evaluations of healthcare and other methodological information (2000).
  • http:/www.cche.net/ebm/userguid/
  • •Website providing user guides for evidence based medicine, including criteria for assessing economic evaluations (1999).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.